1. Aggressive blood pressure reduction and renin–angiotensin system blockade in chronic kidney disease: time for re-evaluation? 
Pantelis A. Sarafidis, Luis M. Ruilope 
Kidney International 
Volume 85, Issue 3, Pages (March 2014)
DOI: /ki
Copyright © 2014 International Society of Nephrology Terms and Conditions

2. Figure 1
Effects of different blood pressure (BP) targets on glomerular filtration rate (GFR) in the Modification of Diet in Renal Disease (MDRD) studies by baseline proteinuria. Low target BP had beneficial effects on GFR slope in patients with proteinuria >0.25g/day in study A and >1g/day in study B. Black circles indicate usual-BP group and white circles indicate low-BP group; numbers in parentheses reflect patients in both BP groups with at least one follow-up GFR measurement
(reprinted from Peterson et al.19).
Kidney International  , DOI: ( /ki )
Copyright © 2014 International Society of Nephrology Terms and Conditions

3. Figure 2
Effects of different blood pressure (BP) targets on the composite outcome of doubling of serum creatinine, end-stage renal disease (ESRD), or death in the trial and cohort phases of the African-American Study on Kidney Disease (AASK
(reprinted from Appel et al.23). P/C, protein/creatinine.
Kidney International  , DOI: ( /ki )
Copyright © 2014 International Society of Nephrology Terms and Conditions

4. Figure 3
Cumulative proportions of patients who reached a renal end point (doubling of serum creatinine or end-stage renal disease (ESRD)) in the Irbesartan Diabetic Nephropathy Trial (IDNT) by quartile of achieved systolic blood pressure (SBP) during follow-up; patients with SBP <134mmHg had the longest renal survival
(reprinted from Pohl et al.27).
Kidney International  , DOI: ( /ki )
Copyright © 2014 International Society of Nephrology Terms and Conditions